The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease. - Wikidata - awgldk - TriplyDB

The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease.

The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease.

http://www.wikidata.org/entity/Q38198098

about

Comparison of two anesthetic methods for intravitreal ozurdex injection Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion Iatrogenic subretinal injection of Ozurdex® implant and its effect on macular edema.The nomadic Ozurdex®: Anterior migration of the dexamethasone implant and back!New Drugs and New Posterior Delivery Methods in CME.Comparison of the effects of intravitreal bevacizumab and dexamethasone in experimental posterior penetrating eye injury.Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients : Corneal endothelium after dexamethasone implant injection Macular cytomegalovirus retinitis following dexamethasone intravitreal implant combined with phacoemulsification Commentary: Iatrogenic cytomegaloviral retinitis following intravitreal steroid implantation

P2860

Q35531482-BF2B1324-6AD3-4229-A575-CDD7AB2B32A2 Q35794470-9070AE9D-603E-4708-9021-A514892F3454 Q41054662-451E17F9-D271-4561-9EF3-FD00466EA622 Q41054688-05440389-58EF-423C-8C00-BA10B19E877A Q50073381-88E383DA-3FBE-49DF-AF61-E18BCF8DC33D Q55007451-5E158DD8-FC66-4D26-BD4D-69E10F7FD322 Q58765745-1CC1E187-AEAA-493E-B1E1-C8DB17E857C8 Q58777189-CF79F676-C5B9-42ED-88F5-660E080E35B6 Q58777377-60C6B8EA-F8FA-4578-A452-D5ABFB8892CA

P2860

The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease.

http://www.wikidata.org/entity/Q38198098

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The Sustained-Release Dexameth ...... ions in Vitreoretinal Disease.

@en

type

label

The Sustained-Release Dexameth ...... ions in Vitreoretinal Disease.

@en

prefLabel

The Sustained-Release Dexameth ...... ions in Vitreoretinal Disease.

@en

P1433

Q38198098-71B2203A-D608-43C7-AF50-AFAD90E9C292

P1476

Q38198098-6323FF62-D618-48D3-9B32-814C00192750

P2093

Q38198098-2226CDAF-63F3-4AF2-B2D0-08AD21165688

Q38198098-BF4DAA99-C8B1-44B2-82D2-CE3E927323F2

Q38198098-F771E9D9-E753-474E-84A0-9CDFB6016877

P2860

Q38198098-137EB7ED-701D-4DA9-B0C3-48E62D1C268D

Q38198098-260A3322-4119-4858-BFB3-3F301FD9208F

Q38198098-2B5FB77B-7CA7-4FD9-A938-30464E6658D7

Q38198098-2FF89C9F-9583-406F-87A5-DCD79B8A7BCF

Q38198098-372CB489-21D4-4BA9-B57D-4DD6F3A7C298

Q38198098-3B555FB0-75C0-448C-B3A7-6954C10DB70E

Q38198098-3F4446ED-F634-4EE4-84A3-093E7388F804

Q38198098-50F3FE7A-D356-4591-BCCE-0665146F5BA7

Q38198098-555C47EF-1B3D-4865-AD7A-B149DBCDA01F

Q38198098-58A722B3-64C8-45DD-B440-CA3EB322689B

P304

Q38198098-0AA98432-5B1D-4959-AC68-8BA2530E8F36

P31

Q38198098-EC814DBA-A3D8-40A3-9F7A-2FDB18448EB6

P356

Q38198098-D18B62FD-DB7C-4870-B8EF-578F57512E83

P407

Q38198098-2E32D632-39A6-42FC-BE0B-361BD25F4A58

P433

Q38198098-EE66EBE9-AB25-4C5C-A850-8587B65177FD

P478

Q38198098-FA972035-2FC3-4D1A-BDC5-05386A72FC9A

P577

Q38198098-B1C9F099-DE5A-4E3B-BBA3-8A588B652704

P698

Q38198098-0ECBF534-1656-44AA-BCF3-61F0FFC03B10

P921

Q38198098-8C1C773E-1B7E-4F96-A5BE-3752DBE4A81B

P356

08820538.2014.889179

P1433

Seminars in Ophthalmology

P1476

The Sustained-Release Dexameth ...... ions in Vitreoretinal Disease.

@en

P2093

A L Wagner

http://www.w3.org/2001/XMLSchema#string

K G Kapoor

http://www.w3.org/2001/XMLSchema#string

M G Wagner

http://www.w3.org/2001/XMLSchema#string

P2860

Short-term results of intravitreal dexamethasone implant (OZURDEX(®)) in treatment of recalcitrant diabetic macular edema: A case series

Intravitreal dexamethasone implant in patients with persistent diabetic macular edema.

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Adult coats' disease successfully managed with the dexamethasone intravitreal implant (ozurdex®) combined with retinal photocoagulation.

Systemic corticosteroid therapy--side effects and their management.

A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.

Vitreous pillow for sustained-release intravitreous drug delivery implants.

Intravitreal dexamethasone implant (ozurdex) in coats' disease.

Subconjunctival dexamethasone implant for non-necrotizing scleritis

Wandering Ozurdex(®) implant.

P304

475-481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/08820538.2014.889179

http://www.w3.org/2001/XMLSchema#string

P407

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24654698

http://www.w3.org/2001/XMLSchema#string

P921